Atezolizumab pediatric population PK
Reference paper ↗A two-compartment population PK model representing pediatric atezolizumab exposure with body weight, albumin, tumor burden, and anti-drug-antibody effects on disposition.
- Therapeutic
- Atezolizumab
- Modality
- Monoclonal antibody
- Target
- PD-L1 / CD274
- Disease
- Pediatric and young-adult malignancies
- Model type
- PopPK
Complete model workspace
Checking workspace access…
- Parameters
- 18
- States
- 4
- Equations
- 4
- Derived outputs
- 33
Explore this model
Choose a starting point to view its result. Adjust key model inputs when you want to explore a different outcome.
Child <30 kg, 15 mg/kg every 3 weeks dynamic scenario
How do pediatric body size and clinical covariates alter atezolizumab concentration and exposure? Explore this intervention regimen through Central atezolizumab concentration, Cumulative atezolizumab exposure, Individual clearance, Individual central volume.
Starting result
This result reflects the starting settings. Run your changes to update it.
Result preview could not load
The generated result could not be loaded. The inputs remain available below.
Starting configuration
Time: 0–210 day; step 0.25
| Input | Default | Available range |
|---|---|---|
| Reference systemic clearance | 0.217 L/day | 0.1085–0.3255 L/day |
| Reference central distribution volume | 3.01 L | 1.505–4.515 L |
| Intercompartmental clearance | 0.183 L/day | 0.0915–0.2745 L/day |
| Reference peripheral distribution volume | 1.36 L | 0.68–2.04 L |
| Body weight | 22.5 kg | 11.25–33.75 kg |
Expected readouts
Central atezolizumab concentration · Exposure (AUC) (ug*day/mL) · Systemic clearance · Central distribution volume
Adjustable model parameters
This public explorer exposes 5 curated parameters. Sign in to edit all 18 declared model parameters.
More key parameters (1)
How the model represents the biology
A two-compartment population PK model representing pediatric atezolizumab exposure with body weight, albumin, tumor burden, and anti-drug-antibody effects on disposition.
Solid arrows show modeled movement or change; two-headed arrows show reversible exchange; dashed arrows show modulation without material transfer.
Model scope: PD-L1 binding or occupancy, immune activation, tumor response, toxicity, and safety outcomes are not represented. This release is a covariate-scaled two-compartment population-PK model.
Modeled relationships (6)
- Repeated IV infusion → Central exposure: infusion rate (flow)
- Central exposure ↔ Peripheral compartment: distribution (reversible exchange)
- Pediatric PK covariates → Central exposure: weight + albumin scale V1 (modulation)
- Pediatric PK covariates → Systemic clearance: scales CL (modulation)
- Central exposure → Systemic clearance: systemic CL (loss)
- Central exposure → Cumulative exposure: integrates C (production)
Modeled relationships: Repeated IV infusion to Central exposure: infusion rate (flow); Central exposure reversibly exchanges with Peripheral compartment: distribution (reversible exchange); Pediatric PK covariates to Central exposure: weight + albumin scale V1 (modulation); Pediatric PK covariates to Systemic clearance: scales CL (modulation); Central exposure to Systemic clearance: systemic CL (loss); Central exposure to Cumulative exposure: integrates C (production).
Primary readouts: Central and peripheral atezolizumab; Cumulative exposure; Covariate-adjusted clearance; Covariate-adjusted central volume.
Related models
Research use only — not for patient-specific prediction or dosing advice.
